Hearts & Minds Blog

Bringing My Life’s Work to Esperion

Tricia Mullins

Executive Director, Advocacy & Professional Relations

As February comes to a close, we reflect on the importance of recognizing American Heart Month, a time dedicated to increasing awareness and education about heart disease and prevention in the U.S.  It is also an opportunity to further focus on cardiovascular disease and talk more about it.  Many believe the burden of cardiovascular disease is under control, but the facts are just the opposite: heart disease is still the #1 cause of death here in the U.S., accounting for nearly 801,000 deaths annually, according to the American Heart Association[1].

Each day, 2,200 Americans die of cardiovascular disease, which translates to an average of one death every 40 seconds. These numbers are very alarming, and it is important that patients at high risk for cardiovascular events have proactive, productive conversations with their doctors and/or health care teams on what they can do NOW to help prevent future serious cardiovascular events.

Prior to joining the Esperion Lipid Management Team, I spent the past 20 years in the biotech and non-profit sectors.  I am thrilled to be contributing my passion for advocacy to serve patients with hypercholesterolemia as a member of the Esperion team.  My life’s work consists of driving patient advocacy efforts to eliminate the challenges many patients face in understanding and managing their diseases.  I am excited to turn my focus to growing the Esperion Advocacy Team and strengthening our initiatives, learning first-hand from interactions about patients’ educational needs, access to care and the need for new, transformative LDL-cholesterol lowering therapies.  I am excited to bring innovative solutions to partner with patients, caregivers, medical societies, patient advocacy organizations and thought leaders worldwide.  We at Esperion are passionately committed to serving patients living with elevated levels of LDL-cholesterol inadequately treated with current lipid-modifying therapies and to developing complementary, cost-effective, convenient, oral, once-daily therapies for patients with hypercholesterolemia and their healthcare providers in the U.S. and around the world.

I look forward to staying in touch on the development and initiation of our patient advocacy efforts and to sharing additional exciting updates with you in the future!

Be Well,

[1] http://newsroom.heart.org/news/new-statistics-show-one-of-every-three-u-s-deaths-caused-by-cardiovascular-disease